Chase Investment Counsel Corp Buys New Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Chase Investment Counsel Corp bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 16,000 shares of the medical equipment provider's stock, valued at approximately $1,431,000.

Several other hedge funds have also added to or reduced their stakes in LNTH. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus during the third quarter valued at approximately $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus in the 4th quarter worth approximately $27,000. UMB Bank n.a. lifted its stake in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after purchasing an additional 134 shares during the period. RiverPark Advisors LLC purchased a new position in shares of Lantheus in the 3rd quarter valued at approximately $74,000. Finally, Farther Finance Advisors LLC boosted its position in shares of Lantheus by 226.7% during the third quarter. Farther Finance Advisors LLC now owns 758 shares of the medical equipment provider's stock valued at $83,000 after purchasing an additional 526 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Insider Activity at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the business's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.50% of the stock is owned by company insiders.

Remove Ads

Lantheus Stock Up 2.4 %

Shares of NASDAQ LNTH traded up $2.31 during trading on Wednesday, reaching $100.48. 1,108,289 shares of the company traded hands, compared to its average volume of 912,095. The firm has a 50 day simple moving average of $90.10 and a 200-day simple moving average of $96.75. Lantheus Holdings, Inc. has a 52-week low of $56.44 and a 52-week high of $126.89. The stock has a market capitalization of $6.88 billion, a PE ratio of 16.72 and a beta of 0.44.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The company had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on LNTH. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. The Goldman Sachs Group began coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective on the stock. Truist Financial lifted their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Finally, JMP Securities restated a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $132.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.